|
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix Clinical research trials and Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix. Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix clinical trial. Human subjects often get the best healthcare possible for their Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix  Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
For Condition: cervical adenocarcinoma,cervical adenosquamous cell carcinoma,recurrent cervical cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Gynecologic Oncology Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have persistent or recurrent cancer of the cervix .
Details: OBJECTIVES: I. Determine the antitumor activity of gemcitabine in patients with persistent or recurrent nonsquamous cell carcinoma of the cervix who failed higher priority treatment protocols. II. Determine the toxicity of this regimen in these patients. PROTOCOL OUTLINE: This is a multicenter study. Patients receive gemcitabine IV over 30 minutes weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years. PROJECTED ACCRUAL: Approximately 15-37 patients will be accrued for this study within 1 year.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of persistent or recurrent nonsquamous cell carcinoma of the cervix that has failed local therapeutic measures and is considered incurable; Eligible subtypes: Adenocarcinoma; Adenosquamous carcinoma; Undifferentiated carcinoma; Must have documented disease progression; Histologic confirmation of original primary tumor required - Bidimensionally measurable disease - Ineligible for higher priority GOG protocol --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent filgrastim (G-CSF) - Chemotherapy: No prior gemcitabine; At least 3 weeks since other prior chemotherapy for cervical cancer and recovered; No more than 1 prior chemotherapy regimen (single or combination cytotoxic therapy) - Endocrine therapy: Not specified - Radiotherapy: At least 3 weeks since prior radiotherapy for cervical cancer and recovered - Surgery: At least 3 weeks since prior surgery for cervical cancer and recovered - Other: No prior cancer treatment that would preclude study --Patient Characteristics-- - Age: 18 and over - Performance status: GOG 0-2 - Life expectancy: Not specified - Hematopoietic: Platelet count at least 100,000/mm3; Granulocyte count at least 1,500/mm3 - Hepatic: Bilirubin no greater than 1.5 times normal SGOT and alkaline phosphatase no greater than 3 times normal - Renal: Creatinine no greater than 1.5 mg/dL - Other: No significant infection; Not pregnant; Fertile patients must use effective contraception; No other invasive malignancy within the past 5 years except nonmelanomatous skin cancer
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RussellSchilder, Study Chair, Gynecologic Oncology Group
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Holden Comprehensive Cancer Center at The University of Iowa
Iowa City, Iowa, 52242-1009
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
United States
Tacoma General Hospital
Tacoma, Washington, 98405
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, 60612
United States
Washington University School of Medicine
St. Louis, Missouri, 63110
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0502
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
Tufts University School of Medicine
Boston, Massachusetts, 02111
United States
Cancer Center of Albany Medical Center
Albany, New York, 12208
United States
Ellis Fischel Cancer Center
Columbia, Missouri, 65203
United States
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
United States
Medical University of South Carolina
Charleston, South Carolina, 29425-0721
United States
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
United States
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
United States
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Canada
Fletcher Allen Health Care - Medical Center Campus
Burlington, Vermont, 05401
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
Brookview Research, Inc.
Nashville, Tennessee, 37203
United States
Abington Memorial Hospital
Abington, Pennsylvania, 19001
United States
Cooper Hospital/University Medical Center
Camden, New Jersey, 08103
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
United States
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, 73190
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104-4283
United States
Community Hospital of Los Gatos
Los Gatos, California, 95032
United States
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
United States
Comprehensive Cancer Center at Wake Forest University
Winston Salem, North Carolina, 27157-1082
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
United States
Walter Reed Army Medical Center
Washington D.C., District of Columbia, 20307-5000
United States
Additional Information:
Study ID Numbers: CDR0000068144; GOG-0128F
Study Start Date: September 2000
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006224
Other Cervical Adenosquamous Cell Carcinoma Studies:
1. Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix
2. Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
3. Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer
4. Comparison of Cisplatin Combined With Either Paclitaxel or Gemcitabine in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
5. DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
Related Studies:
Other cervical adenosquamous cell carcinoma Clinical Trials
Other South Carolina Clinical Trials
Other Charleston Clinical Trials
Gemcitabine in Treating Patients With Persistent or Recurrent Cancer of the Cervix
|
|
|
|
|
|
|
|
